Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Xetra  >  Merck KGaA    MRK   DE0006599905

SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector news 

Merck KGaA Gives Details On Planned Efficiency Program

share with twitter share with LinkedIn share with facebook
share via e-mail
0
02/24/2012 | 05:51pm CET

-- Germany's Merck provides details about efficiency program.

-- Conglomerate joins a long list of drug makers revamping themselves.

-- Merck KGaA shares fall after restructuring update.

(Adds details, share details, background.)

   By Neetha Mahadevan 
   Of  
 

Pharmaceutical and chemical company Merck KGaA (>> Merck KGaA) said Friday it launched a cost-cutting and efficiency plan in the wake of increased price pressures in the U.S. and Europe and a series of drug development setbacks.

The company said the plan could involve job cuts across all businesses and regions to reduce costs and address "unprecedented market shifts", but it didn't disclose details, saying management still needed to speak with relevant stakeholders for a mutually acceptable solution.

"Over the next two years, Merck needs to address unprecedented market shifts, increasing competition in key product areas and existing inefficiencies in its own organization to ensure the long-term success of its business model," Chief Executive Karl-Ludwig Kley said in a statement.

With its new cost-cutting drive, the German chemical and pharmaceutical company joins a long list of other drug makers who are revamping themselves in response to falling sales and profitability.

The need to cut costs is partly due to mounting pressure stemming from health care reforms in the U.S. and Europe, where governments are increasingly reluctant to reimburse expensive drugs and advocate the use of cheaper generic medicines. Companies such as AstraZeneca Plc (AZ.LN), Novartis AG (NVS), Roche Holding AG (ROG.VX), Pfizer Inc (>> Pfizer Inc.), Eli Lilly & Co (>> Eli Lilly & Co.) have all embarked on cost saving or restructuring programs to keep costs under control.

In addition to set-backs in its drug pipeline, Merck has also been hit by a slowdown in demand at its chemicals division, which led to disappointing developments in the last year and prompted it to tighten its outlook time and again.

In the second-quarter, it recorded a 6.5% drop in revenue at its chemicals division, while in the third-quarter profits fell due largely to weakness in its performance materials division.

The efficiency measures are part of Merck's comprehensive transformation program, announced last year, and comprises two phases, the company said.

In the first two years, Merck plans to set up a new leadership organization, implement efficiency measures and focus on long-term growth, while the second phase will be focused on exploiting new growth opportunities, it added.

Merck KGaA shares fell after the news and at 1545 GMT traded down 1.2% at EUR79.70, while the DAX benchmark index traded 0.6% higher.

-By Neetha Mahadevan, Dow Jones Newswires; +49 69 2972 5507; neetha.mahadevan@dowjones.com

(Sten Stovall contributed to this article.)

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on MERCK KGAA
12/08 MERCK : Chelmsford High School Students explore life sciences careers
12/08 BIOCARTIS GROUP NV : Biocartis launches second liquid biopsy assay - Assay co-de..
12/06 MERCK : Consumer Health business drives consumer-centric, purposeful innovation
12/06 MERCK : s Consumer Health Business Drives Consumer-Centric, Purposeful Innovatio..
12/05 RONASTAR® RED ALLURE : The elegant, matte pigment innovation from Merck
12/05 MERCK : to Provide Provantage® End-to-End Services to Acticor Biotech SAS
12/02 MERCK : Launches Parteck® MXP Excipient for Increased Solubility
12/01 MERCK : Expands Distribution Agreement with Roche
12/01 QuintilesIMS Forms New Collaboration with Bristol-Myers Squibb, Lilly, Merck ..
12/01 DGAP-PVR : Merck KGaA: Release according to Article 26, Section 1 of the WpHG w..
More news
Sector news : Specialty & Advanced Pharmaceuticals
04:31pDJASTRAZENECA : FDA Accepts License Application for Durvalumab
02:05pDJBayer Teams Up With Versant to Develop Stem-Cell Therapies--Update
12/08 BRISTOL MYERS SQUIBB : Meyers Squibb to pay $19.5 million to settle off-label pr..
12/07 MYLAN : EpiPen maker Mylan to restructure, cut workforce
12/07DJABBOTT LABORATORIES : Seeks to Terminate Alere Deal -- Update
More sector news : Specialty & Advanced Pharmaceuticals
News from SeekingAlpha
12/01 Roche expands distribution partnership with Merck KGaA
11/30 Evotec and Merck KGaA team up to discover new therapeutic targets
11/29 FDA accepts avelumab BLA under Priority Review for rare type of skin cancer
11/22 QuintilesIMS forms collaboration with major drug firms to better understand r..
11/15 Merck KGaA 2016 Q3 - Results - Earnings Call Slides
Advertisement
Financials (€)
Sales 2016 15 095 M
EBIT 2016 3 561 M
Net income 2016 1 782 M
Debt 2016 11 024 M
Yield 2016 1,36%
P/E ratio 2016 21,84
P/E ratio 2017 20,66
EV / Sales 2016 1,52x
EV / Sales 2017 1,35x
Capitalization 11 977 M
More Financials
Chart MERCK KGAA
Duration : Period :
Merck KGaA Technical Analysis Chart | MRK | DE0006599905 | 4-Traders
Full-screen chart
Technical analysis trends MERCK KGAA
Short TermMid-TermLong Term
TrendsNeutralNeutralBullish
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 25
Average target price 107 €
Spread / Average Target 15%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Stefan Oschmann Chief Executive Officer
Wolfgang Heinz Büchele Chairman-Supervisory Board
Marcus Kuhnert Chief Financial Officer
Crocifissa Attardo Member-Supervisory Board
Mechthild Auge Member-Supervisory Board
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
MERCK KGAA2.65%12 712
ABBVIE INC2.80%98 969
KYOWA HAKKO KIRIN CO L..-20.26%7 648
JAZZ PHARMACEUTICALS P..-27.58%6 097
MALLINCKRODT PLC-29.85%5 542
ZHANGZHOU PIENTZEHUANG..1.57%4 078
More Results